Structure of full-length APOBEC3B bound to EBV BORF2 reveals coordinated neutralization of a cancer-associated mutator

Abstract

The double-domain APOBEC3B (A3B) contains an N-terminal non-catalytic and C-terminal active cytidine deaminase domains (NTD and CTD). A3B restricts viral infection yet is also a major endogenous mutator in human cancer, driving tumor evolution and drug resistance. A previous study showed that the Epstein-Barr virus (EBV) ribonucleotide reductase large subunit BORF2 binds the active site of the A3B CTD and neutralizes the activity of the isolated catalytic domain. However, the three-dimensional organization of full-length A3B (fl-A3B) and the contribution of A3B NTD to BORF2-mediated neutralization have remained unclear. Here, we report a 2.77 [A] cryo-electron microscopy structure of fl-A3B in complex with EBV BORF2. The structure reveals an elongated hetero-octamer comprising two A3B2/BORF22 tetramers linked through alternating canonical and non-canonical BORF2 dimer interfaces. Full-length A3B adopts a defined NTD-CTD arrangement distinct from previously characterized APOBEC3G conformations. The A3B CTD binds BORF2 and occludes access to the catalytic site, while the A3B NTD simultaneously contacts a second BORF2 subunit, stabilizing a previously uncharacterized BORF2 canonical dimer interface required for higher-order assembly. Disruption of either BORF2 dimer interface prevents formation of filamentous A3B-BORF2 assemblies. These findings establish the structural architecture of full-length A3B and reveal how dual-domain engagement by A3B promotes higher-order BORF2 assembly, providing a structural framework for understanding EBV-mediated neutralization of an antiviral and cancer-associated mutator.